2Asci-Buturovi B,Kacila M,Kuli M.Effects of aggressive approach to the multiple risk factors for diabetic nephro-pathy on proteinuria reduction in diabetes type 2 patients[J].Bosn J Basic Med Sci,2009,9(1):44-48.
3ADA.Standards of medical care in diabetes-2009[J].Diabetes Care,2009,32(l):13-61.
4The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2008,358(24):2560-2572.
5Keech A,Simes RJ,Barter P,et al.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial[J].Lancet,2005,366(9500):1849-1861.
6Parving HH,Persson F,Lewis JB,et al.Aliskiren combined with losartan in type 2 diabetes and nephropathy[J].N Engl J Med,2008,358(23):2433-2446.
7Gavrila D,Li WG,McCormick ML,et al.Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice[J].Arterioseler Thromb Vase Biol,2005,25(8):1671-1677.
9Kim SK,Jung KH,Lee BC.Protective effect of Tanshinone ⅡA on the early stage of experimental diabetic nephropathy[J].Biol Pharm Bull,2009,32(2):220-224.
